MedPath
Found 44 clinical trials|View Analysis
Sort by:

Immunotherapy Before and After Surgery

Phase 2
Not yet recruiting
Conditions
High-risk Prostate Cancer
Interventions
Drug: N-803
Drug: ETBX-071
Drug: M-CENK
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
20
Registration Number
NCT06765902

Open-Label, Phase 2 Clinical Trial of Pre-Radiation and Post-Radiation Immunotherapy with N 803, ETBX-071, and M-CENK in Combination with Radiation for Participants with High-Risk Prostate Cancer.

Phase 2
Not yet recruiting
Conditions
High-risk Prostate Cancer
Interventions
Drug: N-803 (IL-15 Superagonist)
Drug: ETBX-071 (PSA-based Oncolytic Virus)
Drug: M-CENK (Activated NK Cells)
Radiation: External Beam Radiation Therapy (EBRT)
Radiation: Androgen Deprivation Therapy (ADT)
Radiation: Post-radiation immunotherapy
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
20
Registration Number
NCT06765954

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Phase 2
Recruiting
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Drug: Gemcitabine
Biological: N-803
Biological: M-CENK
First Posted Date
2024-11-29
Last Posted Date
2024-12-04
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
20
Registration Number
NCT06710288
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Early Phase 1
Not yet recruiting
Conditions
Renal Carcinoma
Renal Cell Carcinoma
Urothelial Carcinoma
Chromophobe Renal Cell Carcinoma
Interventions
Biological: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
Drug: Interleukin-2 (IL-2)
First Posted Date
2024-03-19
Last Posted Date
2024-07-30
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
5
Registration Number
NCT06318871
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1
Suspended
Conditions
Endometrial Cancer
Cancer of Endometrium
Carcinoma of Endometrium
Endometrial Carcinoma
Interventions
Biological: AdHER2DC vaccine
Biological: Pembrolizumab
Drug: Lenvatinib
Biological: N-803
Device: PATHWAY HER2 (4B5) assay
First Posted Date
2024-02-12
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06253494
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PD-L1 T-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Phase 2
Recruiting
Conditions
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Metastatic Head-and-neck Squamous-cell Carcinoma
Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Biological: PD-L1 t-haNK
Drug: Cetuximab
Biological: N-803
First Posted Date
2024-02-02
Last Posted Date
2024-10-26
Lead Sponsor
Glenn J. Hanna
Target Recruit Count
25
Registration Number
NCT06239220
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Phase 2
Not yet recruiting
Conditions
Stage IV Squamous Cell Carcinoma of the Head and Neck
Stage II Squamous Cell Carcinoma of the Head and Neck
Stage III Squamous Cell Carcinoma of the Head and Neck
Interventions
Drug: N-803
Drug: pembrolizumab
Biological: PD-L1 t-haNK cells
First Posted Date
2023-12-08
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
40
Registration Number
NCT06161545
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Phase 1
Recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Retifanlimab
Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Drug: N-803
Drug: SX-682
First Posted Date
2023-11-29
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06149481
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2
Recruiting
Conditions
Glioblastoma
Interventions
Drug: Bevacizumab
Drug: PD-L1 t-haNK
Drug: N-803
First Posted Date
2023-09-29
Last Posted Date
2024-08-19
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
20
Registration Number
NCT06061809
Locations
🇺🇸

Providence Medical Foundation, Fullerton, California, United States

🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Phase 1
Recruiting
Conditions
Healthy Subjects
Interventions
Drug: N-803
First Posted Date
2023-09-18
Last Posted Date
2024-01-29
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
10
Registration Number
NCT06040918
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

© Copyright 2025. All Rights Reserved by MedPath